Cargando…

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain

Purpose: The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C viral (HCV) infection. This study aims to establish real-world treatment efficacy of Sofosbuvir-based (SOF-B) and Ombitasvir/Paritaprevir/Ritonavir-based (OPR-B) regimens. Patients an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdulla, Maheeba, Ali, Hamed, Nass, Hafsa, Khamis, Jawad, AlQamish, Jehad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524762/ https://www.ncbi.nlm.nih.gov/pubmed/31191049 http://dx.doi.org/10.2147/HMER.S190967

Ejemplares similares

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Overview on the endoscopic treatment for obesity: A review
por: Abdulla, Maheeba, et al.
Publicado: (2023)

Prevalence of hepatitis B e antigenemia in Bahraini hepatitis B patients: A retrospective, single‐center study
por: Abdulla, Maheeba, et al.
Publicado: (2021)

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
por: Abdulla, Maheeba A, et al.
Publicado: (2017)

A prospective study of the association between sickle cell disease and hepatobiliary effects in Bahrain
por: Abdulla, Maheeba A M, et al.
Publicado: (2017)

Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain: Real world experience
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Inflammatory bowel disease in Bahrain: single-center experience
por: Abdulla, Maheeba, et al.
Publicado: (2017)

Effect of COVID-19 on liver abnormalities: a systematic review and meta‐analysis
por: Bzeizi, Khalid, et al.
Publicado: (2021)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Lung Cancer in Bahrain (1952–2004)
por: Alhilli, Fayek A., et al.
Publicado: (2007)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Distribution of Hepatitis C Virus Genotypes in Bahrain
por: Janahi, Essam M., et al.
Publicado: (2015)

Hepatitis B Virus Genotypes in the Kingdom of Bahrain: Prevalence, Gender Distribution and Impact on Hepatic Biomarkers
por: Janahi, Essam M., et al.
Publicado: (2019)

First Case of Dendriform Pulmonary Ossification in Bahrain
por: Naser, Naser, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2020)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
por: Ko, Soon Young, et al.
Publicado: (2018)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy
por: Llorens-Revull, Meritxell, et al.
Publicado: (2021)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Spatial and temporal analysis of the risks posed by metal contamination in coastal and marine sediments of Bahrain
por: Nicolaus, E. E. M., et al.
Publicado: (2022)

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
por: Loo, Nicole, et al.
Publicado: (2019)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018)

Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2019)

Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3qo1iufveqila7st6jqqktui8g